Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Aurinia Pharmaceuticals Inc is a biotechnology business based in the US. Aurinia Pharmaceuticals shares (AUPH) are listed on the NASDAQ and all prices are listed in US Dollars. Aurinia Pharmaceuticals employs 62 staff and has a trailing 12-month revenue of around USD$318,000.
|Latest market close||USD$14.25|
|52-week range||USD$3.52 - USD$21.93|
|50-day moving average||USD$14.3754|
|200-day moving average||USD$15.0362|
|Wall St. target price||USD$11.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.697|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-22)||-3.85%|
|1 month (2020-08-28)||3.49%|
|3 months (2020-06-29)||-6.25%|
|6 months (2020-03-27)||-0.77%|
|1 year (2019-09-27)||161.47%|
|2 years (2018-09-28)||114.61%|
|3 years (2017-09-29)||127.27%|
|5 years (2015-09-29)||410.75%|
|Gross profit TTM||USD$-52,548,000|
|Return on assets TTM||-27.23%|
|Return on equity TTM||-77.6%|
|Market capitalisation||USD$1.8 billion|
TTM: trailing 12 months
There are currently 4.4 million Aurinia Pharmaceuticals shares held short by investors – that's known as Aurinia Pharmaceuticals's "short interest". This figure is 6.1% up from 4.1 million last month.
There are a few different ways that this level of interest in shorting Aurinia Pharmaceuticals shares can be evaluated.
Aurinia Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aurinia Pharmaceuticals shares currently shorted divided by the average quantity of Aurinia Pharmaceuticals shares traded daily (recently around 1.2 million). Aurinia Pharmaceuticals's SIR currently stands at 3.64. In other words for every 100,000 Aurinia Pharmaceuticals shares traded daily on the market, roughly 3640 shares are currently held short.
However Aurinia Pharmaceuticals's short interest can also be evaluated against the total number of Aurinia Pharmaceuticals shares, or, against the total number of tradable Aurinia Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aurinia Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Aurinia Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Aurinia Pharmaceuticals shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aurinia Pharmaceuticals.
Find out more about how you can short Aurinia Pharmaceuticals stock.
We're not expecting Aurinia Pharmaceuticals to pay a dividend over the next 12 months.
Aurinia Pharmaceuticals's shares were split on a 1:50 basis on 23 October 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aurinia Pharmaceuticals shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Aurinia Pharmaceuticals shares which in turn could have impacted Aurinia Pharmaceuticals's share price.
Over the last 12 months, Aurinia Pharmaceuticals's shares have ranged in value from as little as $3.52 up to $21.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aurinia Pharmaceuticals's is 0.9797. This would suggest that Aurinia Pharmaceuticals's shares are less volatile than average (for this exchange).
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.